Showing results (71-80 of 89) with videos related to

Sort By:
Pageof 9
Diabetes Care|May 26, 2021
The Impact of Frailty on the Effectiveness and Safety of Intensive Glucose Control and Blood Pressure-Lowering Therapy for People With Type 2 Diabetes: Results From the ADVANCE TrialTu N Nguyen, Katie Harris, Mark Woodward, et al.
Plos One|February 8, 2013
Effects of the endpoint adjudication process on the results of a randomised controlled trial: the ADVANCE trialJun Hata, Hisatomi Arima, Sophia Zoungas, et al.
Diabetes Care|March 24, 2016
Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ONMuh Geot Wong, Vlado Perkovic, John Chalmers, et al.
Hypertension (Dallas, Tex. : 1979)|July 14, 2010
Monitoring initial response to Angiotensin-converting enzyme inhibitor-based regimens: an individual patient data meta-analysis from randomized, placebo-controlled trialsKaty J L Bell, Andrew Hayen, Petra Macaskill, et al.
Journal of Hypertension|May 21, 2010
Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trialToshiharu Ninomiya, Sophia Zoungas, Bruce Neal, et al.
Journal of the American Society of Nephrology : JASN|May 16, 2009
Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetesToshiharu Ninomiya, Vlado Perkovic, Bastiaan E de Galan, et al.
Diabetes Care|August 5, 2009
Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trialSophia Zoungas, Bastiaan E de Galan, Toshiharu Ninomiya, et al.
Journal of the American Society of Nephrology : JASN|February 20, 2009
Lowering blood pressure reduces renal events in type 2 diabetesBastiaan E de Galan, Vlado Perkovic, Toshiharu Ninomiya, et al.
European Heart Journal|June 12, 2010
Genetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery diseaseJasper Jan Brugts, Aaron Isaacs, Eric Boersma, et al.
Journal of Hypertension|December 16, 2010
A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individualsJasper J Brugts, Aaron Isaacs, Moniek Pm de Maat, et al.
Pageof 9